Leveraging a national biorepository in Zambia to assess measles and rubella immunity gaps across age and space.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
17 06 2022
17 06 2022
Historique:
received:
13
09
2021
accepted:
08
06
2022
entrez:
17
6
2022
pubmed:
18
6
2022
medline:
22
6
2022
Statut:
epublish
Résumé
High-quality, representative serological surveys allow direct estimates of immunity profiles to inform vaccination strategies but can be costly and logistically challenging. Leveraging residual serum samples is one way to increase their feasibility. We subsampled 9854 residual sera from a 2016 national HIV survey in Zambia and tested these specimens for anti-measles and anti-rubella virus IgG antibodies using indirect enzyme immunoassays. We demonstrate innovative methods for sampling residual sera and analyzing seroprevalence data, as well as the value of seroprevalence estimates to understand and control measles and rubella. National measles and rubella seroprevalence for individuals younger than 50 years was 82.8% (95% CI 81.6, 83.9%) and 74.9% (95% CI 73.7, 76.0%), respectively. Despite a successful childhood vaccination program, measles immunity gaps persisted across age groups and districts, indicating the need for additional activities to complement routine immunization. Prior to vaccine introduction, we estimated a rubella burden of 96 congenital rubella syndrome cases per 100,000 live births. Residual samples from large-scale surveys can reduce the cost and challenges of conducting serosurveys, and multiple pathogens can be tested. Procedures to access quality specimens, ensure ethical approvals, and link sociodemographic data can improve the timeliness and value of results.
Identifiants
pubmed: 35715547
doi: 10.1038/s41598-022-14493-3
pii: 10.1038/s41598-022-14493-3
pmc: PMC9204687
doi:
Substances chimiques
Antibodies, Viral
0
Measles-Mumps-Rubella Vaccine
0
Rubella Vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10217Subventions
Organisme : Bill & Melinda Gates Foundation
ID : OPP1094816
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28506-28514
pubmed: 33106403
Lancet Infect Dis. 2021 Feb;21(2):286-295
pubmed: 32888410
Nature. 2021 Jan;589(7842):415-419
pubmed: 33328634
PLoS Med. 2013;10(5):e1001404
pubmed: 23667334
Stat Med. 2021 Apr;40(9):2197-2211
pubmed: 33540473
Lancet. 2012 Jul 21;380(9838):217-8
pubmed: 22817974
Trans R Soc Trop Med Hyg. 2000 May-Jun;94(3):333-40
pubmed: 10975015
MMWR Morb Mortal Wkly Rep. 2020 Nov 13;69(45):1700-1705
pubmed: 33180759
Vaccine. 2018 Jun 27;36(28):4001-4003
pubmed: 29793892
Am J Epidemiol. 2018 Oct 1;187(10):2219-2226
pubmed: 29878051
Trop Med Int Health. 2016 Sep;21(9):1086-98
pubmed: 27300255
Emerg Infect Dis. 2018 Jul;24(7):1188-1194
pubmed: 29912680
Proc Natl Acad Sci U S A. 2020 Dec 1;117(48):30118-30125
pubmed: 33203683
Lancet. 2012 Jun 9;379(9832):2173-8
pubmed: 22534001
Spat Spatiotemporal Epidemiol. 2018 Jun;25:25-37
pubmed: 29751890
BMC Med. 2019 Sep 25;17(1):180
pubmed: 31551070
J Infect Dis. 2018 Jul 2;218(3):355-364
pubmed: 29562334
PLoS One. 2013 Jul 05;8(7):e67639
pubmed: 23861777
Science. 2015 Mar 13;347(6227):1240-2
pubmed: 25766232
Science. 2021 Jan 1;371(6524):79-82
pubmed: 33177105
Emerg Infect Dis. 2013 Feb;19(2):202-9
pubmed: 23343504
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Vaccine. 2019 Jan 29;37(5):732-741
pubmed: 30579756
J Infect Dis. 2007 Aug 1;196(3):347-55
pubmed: 17597448
J Biosoc Sci. 1992 Apr;24(2):201-9
pubmed: 1583034
PLoS One. 2016 Mar 10;11(3):e0149160
pubmed: 26962867
Lancet. 2021 Aug 7;398(10299):522-534
pubmed: 34273292
Vaccine. 2019 Apr 17;37(17):2387-2393
pubmed: 30905529
Lancet Infect Dis. 2017 Oct;17(10):1089-1097
pubmed: 28807627
BMC Infect Dis. 2020 Feb 3;20(1):101
pubmed: 32013873